CC
BMY.RT

Carlson Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Carlson Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-875,000
Closed -$604K – 225
2020
Q4 		$604K Sell
875,000
-293,896
-25% -$626K 0.02% 147
2020
Q3 		$2.63M Buy
1,168,896
+243,896
+26% +$697K 0.08% 157
2020
Q2 		$3.31M Buy
925,000
+490,000
+113% +$1.77M 0.09% 142
2020
Q1 		$1.65M Buy
435,000
+159,112
+58% +$524K 0.04% 164
2019
Q4 		$830K Buy
+275,888
New +$717K 0.02% 220

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Carlson Capital's BMY.RT Position: Q1 2021 in Review

Carlson Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 875,000 shares — an estimated $604K sold.

Carlson Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.31M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Carlson Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Carlson Capital sold 875,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $604K.
  • Carlson Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Carlson Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.31M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Carlson Capital's 13F filing for Q1 2021, filed 13 May 2021.